JP2005507648A5 - - Google Patents

Download PDF

Info

Publication number
JP2005507648A5
JP2005507648A5 JP2003514007A JP2003514007A JP2005507648A5 JP 2005507648 A5 JP2005507648 A5 JP 2005507648A5 JP 2003514007 A JP2003514007 A JP 2003514007A JP 2003514007 A JP2003514007 A JP 2003514007A JP 2005507648 A5 JP2005507648 A5 JP 2005507648A5
Authority
JP
Japan
Prior art keywords
polypeptide
compound
nucleic acid
ntb
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003514007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005507648A (ja
JP4326944B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/007945 external-priority patent/WO2003008449A1/en
Publication of JP2005507648A publication Critical patent/JP2005507648A/ja
Publication of JP2005507648A5 publication Critical patent/JP2005507648A5/ja
Application granted granted Critical
Publication of JP4326944B2 publication Critical patent/JP4326944B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003514007A 2001-07-19 2002-07-17 ナチュラルキラー細胞活性に関与する表面分子ntb−a Expired - Fee Related JP4326944B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01401946 2001-07-19
PCT/EP2002/007945 WO2003008449A1 (en) 2001-07-19 2002-07-17 Ntb-a, a surface molecule involved in natural killer cells activity

Publications (3)

Publication Number Publication Date
JP2005507648A JP2005507648A (ja) 2005-03-24
JP2005507648A5 true JP2005507648A5 (enExample) 2006-01-05
JP4326944B2 JP4326944B2 (ja) 2009-09-09

Family

ID=8182813

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003514007A Expired - Fee Related JP4326944B2 (ja) 2001-07-19 2002-07-17 ナチュラルキラー細胞活性に関与する表面分子ntb−a

Country Status (8)

Country Link
US (2) US7138243B2 (enExample)
EP (1) EP1406928B1 (enExample)
JP (1) JP4326944B2 (enExample)
AT (1) ATE464320T1 (enExample)
AU (1) AU2002325333B2 (enExample)
CA (1) CA2454185A1 (enExample)
DE (1) DE60235985D1 (enExample)
WO (1) WO2003008449A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04001986A (es) * 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
WO2006070286A2 (en) 2004-12-28 2006-07-06 Innate Pharma S.A. Monoclonal antibodies against nkg2a
NO346945B1 (no) 2006-06-30 2023-03-13 Novo Nordisk As Anti-NKG2A-antistoffer og anvendelser derav
US7847067B2 (en) * 2006-08-28 2010-12-07 ARCA Biopharma Antibodies to NTB-A
RU2010133892A (ru) 2008-01-24 2012-02-27 Ново Нордиск А/С (DK) Гуманизированные моноклональные антитела против человеческого nkg2a
CA2838220C (en) 2011-06-17 2020-07-21 Novo Nordisk A/S Use of nkg2a antibodies for treatment of bone loss
CA2893977C (en) * 2012-12-21 2024-02-13 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
US10344073B2 (en) 2014-01-09 2019-07-09 Hadasit Medical Research Services And Development Ltd. Cell compositions and methods for cancer therapy
AU2016299166B2 (en) 2015-07-24 2022-03-31 Innate Pharma Methods for detecting tissue infiltrating NK cells
US11110171B2 (en) 2017-12-21 2021-09-07 New York University PD-1 related cancer therapy
EP3752252A4 (en) 2018-02-12 2021-11-17 Hadasit Medical Research Services and Development Ltd. MODULATION OF SLAMF6 SPLICE VARIANTS FOR CANCER TREATMENT
JP7616610B2 (ja) * 2020-06-09 2025-01-17 サムスン ライフ パブリック ウェルフェア ファウンデーション Nk細胞の活性化及び増幅のために遺伝的に操作された細胞株、及びその用途
CN116179488A (zh) * 2023-03-09 2023-05-30 广东唯泰生物科技有限公司 外周血自然杀伤细胞的体外扩增方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4337197C1 (de) * 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
WO2002024888A2 (en) * 2000-09-01 2002-03-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1252333A4 (en) * 2000-01-25 2005-01-05 Nuvelo Inc METHODS AND SUBSTANCES RELATING TO CD84-TYPE POLYPEPTIDES AND POLYNUCLEOTIDES
US7029677B2 (en) * 2000-01-25 2006-04-18 Nuvelo, Inc. Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
AU2001274888A1 (en) * 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030180888A1 (en) * 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
EP1223218A1 (en) * 2000-11-03 2002-07-17 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules and uses thereof
EP1377597A4 (en) * 2001-03-22 2005-02-09 Bristol Myers Squibb Co POLYNUCLEOTIDE CODING FOR A NEW MEMBER OF THE IMMUNOGLOBULIN SUPERFAMILY, APEX4, AND ITS VARIATIONS AND SPICE VARIANTS

Similar Documents

Publication Publication Date Title
JP2006515749A5 (enExample)
JP2003501038A5 (enExample)
JP2011509073A5 (enExample)
JP2005504513A5 (enExample)
JP2005507648A5 (enExample)
JP2004512824A5 (enExample)
JP2007297407A5 (enExample)
JP2012115275A5 (enExample)
CA2316280A1 (en) Novel g protein-coupled receptor
JP2017514481A5 (enExample)
JP2009529917A5 (enExample)
JP2004512006A5 (enExample)
WO2010065407A2 (en) High affinity recombinant sea lamprey antibodies selected by a yeast surface display platform
JP2005523681A5 (enExample)
CA2443345A1 (en) Disease-associated protein
JP2007526759A5 (enExample)
JP2008502355A5 (enExample)
EP4667484A1 (en) Homodimeric protein combining human il-1r1 with human il-1racp polypeptide fragments and use
JP2005511023A5 (enExample)
JPH1066585A5 (enExample)
JP2007508020A5 (enExample)
JP2006502738A5 (enExample)
JP2017525368A5 (enExample)
JP2005516604A5 (enExample)
JP2005528894A5 (enExample)